Compounds > mw-151
Page last updated: 2024-11-12

mw-151

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(4-(4-methyl-6-phenylpyridazin-3-yl)piperazin-1-yl)pyrimidine: attenuates proinflammatory cytokine production [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11515480
CHEMBL ID232211
SCHEMBL ID1752767
MeSH IDM0578462

Synonyms (19)

Synonym
4-methyl-6-phenyl-3-(4-pyrimidin-2-ylpiperazin-1-yl)pyridazine
mw-151
CHEMBL232211
minozac free base
mw151
ASVQCPUSQNFHHU-UHFFFAOYSA-N
2-(4-(4-methyl-6-phenylpyridazin-3-yl)piperazin-1-yl)pyrimidine
pyridazine, 4-methyl-6-phenyl-3-[4-(2-pyrimidinyl)-1-piperazinyl]-
886208-65-7
flx2owq78o ,
unii-flx2owq78o
pyridazine, 4-methyl-6-phenyl-3-(4-(2-pyrimidinyl)-1-piperazinyl)-
mw-01-2-151srm
SCHEMBL1752767
DTXSID80467910
mw01-2-151srm
AKOS028113684
FT-0741999
Q27278058
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1854711Neuroprotective activity against in OGD/R-induced mouse BV-2 cell injury assessed as cell viability at 1 uM measured after 24 hrs by MTT assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
AID1854715Antiinflammatory activity in LPS-stimulated mouse BV-2 cells assessed as inhibition of IL-6 release at 10 uM and measured after 8 hrs by ELISA2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
AID292782Cardiotoxicity in guinea pig assessed as prolongation of QTc interval at 15 mg/kg, po2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
AID1854712Neuroprotective activity against in OGD/R-induced mouse BV-2 cell injury assessed as cell viability at 10 uM measured after 24 hrs by MTT assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
AID292785Suppression of TNFalpha production in human amyloid-beta induced mouse injury model at 2.5 mg/kg, po for 2 weeks after 60 days of injury2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
AID292784Suppression of IL1-beta production in human amyloid-beta induced mouse injury model at 2.5 mg/kg, po for 2 weeks after 60 days of injury2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
AID292787Reduction of GFAP-positive astrocytes in human amyloid-beta induced mouse injury model at 2.5 mg/kg, po for 2 weeks after 60 days of injury2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
AID292789Prevention of loss of synaptic protein synaptophytsin in human amyloid-beta induced mouse injury model2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
AID1854714Antiinflammatory activity in LPS-stimulated mouse BV-2 cells assessed as inhibition of IL-1beta release at 10 uM and measured after 8 hrs by ELISA2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
AID292780Aqueous solubility of the compound2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
AID1854710Neuroprotective activity against in OGD/R-induced mouse BV-2 cell injury assessed as cell viability at 0.1 uM measured after 24 hrs by MTT assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
AID292791Attenuation of hippocampal dependent behavioral deficits in mouse by Y maze test2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
AID292788Reduction of F4/80 positive microglia in human amyloid-beta induced mouse injury model at 2.5 mg/kg, po for 2 weeks after 60 days of injury2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
AID292786Suppression of S100B production in human amyloid-beta induced mouse injury model at 2.5 mg/kg, po for 2 weeks after 60 days of injury2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
AID292790Prevention of loss of synaptic protein PSD95 in human amyloid-beta induced mouse injury model2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
AID292779Inhibition of IL1 beta production in glia cells2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
AID292783Brain penetration, LogBB of the compound2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
AID1854716Antiinflammatory activity in LPS-stimulated mouse BV-2 cells assessed as inhibition of PGE2 release at 10 uM and measured after 8 hrs by ELISA2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
AID1854713Antiinflammatory activity in LPS-stimulated mouse BV-2 cells assessed as inhibition of TNF-alpha release at 10 uM and measured after 8 hrs by ELISA2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
AID1854717Antiinflammatory activity in LPS-stimulated mouse BV-2 cells assessed as inhibition of NO production at 10 uM and measured after 24 hrs by Griess method2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.11 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.24 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
celecoxib
[no description available]		2.4110organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.4110aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
edaravone
[no description available]		2.4110pyrazoloneantioxidant;
radical scavenger
minaprine
minaprine: Agr 1240 refers to di-HCl; short-acting type A MAO inhibitor (MAOI) of mild potency; structure		2.0310morpholines;
pyridazines;
secondary amine		antidepressant;
antiparkinson drug;
cholinergic drug;
dopamine uptake inhibitor;
serotonin uptake inhibitor
zileuton
[no description available]		2.41101-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
3-n-butylphthalide
3-n-butylphthalide: isolated from phenolic part of Ligusticum wallichii Franch; structure given in first source		2.4110benzofurans
mobic
Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.		2.41101,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Confusional Senile Dementia
[description not available]		02.7630
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.7630
Apoplexy
[description not available]		02.4110
Acute Ischemic Stroke
[description not available]		02.4110
Cerebral Ischemia
[description not available]		02.4110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.0440
Ischemic Stroke
Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.		02.4110
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		02.4110
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)		02.4110
Cognition Disorders
Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.		02.7930
Innate Inflammatory Response
[description not available]		02.0810
Experimental Radiation Injuries
[description not available]		02.0810
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0810
Injuries, Radiation
[description not available]		02.110
Acute Brain Injuries
[description not available]		02.5220
Brain Injuries
Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.		02.5220
Disease Exacerbation
[description not available]		02.4920
Closed Head Injuries
[description not available]		02.1110
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.4920